Drug study for cancers with HRR gene or HRD changes
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 75 (inclusive).
- You have an advanced solid tumor with at least one measurable tumor spot on scans.
- Your cancer has a specific DNA repair issue (HRR gene mutation, or HRD-positive ovarian cancer), and standard treatments didn’t work, aren’t tolerated, or aren’t available.
- Your cancer care team says you’re well enough to function (ECOG score 0–1).
- You’re expected to live longer than 12 weeks.
- You can safely avoid pregnancy during the study (and you’re not breastfeeding), and you can sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HS-10370 given along with other anticancer treatments for advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if this combination is safe and effective for people who have run out of standard options.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
This early study (Phase 1) tests whether HRS-1167 can be given safely to people with advanced solid tumors. It also looks for early signs of activity, especially in cancers with HRR gene mutations (like ovarian, breast, pancreatic, and prostate cancers).
This trial tests a new drug, HRS-7058, combined with other anti-cancer drugs for people with advanced solid tumors that cannot be surgically removed. The goal is to see if the combination can shrink tumors or slow their growth.
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
This trial tests a new drug, HS-20117, for people with advanced solid tumors, especially certain types of lung cancer. It aims to see if the drug is safe and effective when other treatments have stopped working.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.